EKDV‑691 is the first commercially‑available from Ekard Technologies . It bridges the gap between classical silicon and superconducting qubits, delivering 10 × the performance of today’s high‑end CPUs while offering a seamless path to hybrid quantum‑classical workloads. In this post we’ll unpack the architecture, dive into its technical specs, explore real‑world use‑cases, and discuss the broader impact on the computing ecosystem.

Inside the chamber, a of pure energy stood ajar, its surface rippling like the surface of a pond. Beyond it lay a tunnel of light , extending into a dimension that seemed to fold space itself .

| Attribute | Details | |-----------|---------| | | EKDV‑691 (development code) | | Chemical class | Ortho‑aryl‑pyrimidine small‑molecule kinase inhibitor | | Primary target | Dual inhibition of TGF‑β‑type I receptor (ALK5) and DDR1 (Discoidin Domain‑Receptor‑1) | | Therapeutic focus | Fibrotic diseases (idiopathic pulmonary fibrosis, systemic sclerosis) and oncology (desmoplastic tumours) | | Developer | Evoke Therapeutics, Inc. (formerly EK‑Discovery) | | Current status (April 2026) | IND filed (US, EU); Phase I dose‑escalation completed; Phase Ib/IIa trial launched in idiopathic pulmonary fibrosis (IPF) (NCT05891234) | | Formulation | Oral tablets (10 mg, 30 mg, 60 mg) | | Key differentiators | Simultaneous blockade of fibrogenic TGF‑β signaling and collagen‑receptor mediated matrix remodeling; favourable PK/PD profile with once‑daily dosing; low off‑target activity on the cardiac hERG channel. |